Caterpillar Down 7%, On Pace For Largest Percent Decrease Since April 2025 -- Data Talk
Dow Jones2026/10/29 15:06Caterpillar Inc. (CAT) is currently at $663.46, down $49.92 or 7%
--Would be lowest close since Jan. 30, 2026, when it closed at $657.36
--On pace for largest percent decrease since April 3, 2025, when it fell 8.64%
--Snaps a three day winning streak
--Down 18.17% month-to-date; on pace for worst month since July 2026, when it fell 23.48%
--Up 15.81% year-to-date
--Down 37.7% from its all-time closing high of $1064.90 on June 30, 2026
--Up 13.77% from 52 weeks ago (Oct. 30, 2025), when it closed at $583.15
--Down 37.7% from its 52-week closing high of $1064.90 on June 30, 2026
--Up 21.48% from its 52-week closing low of $546.13 on Nov. 20, 2025
--Traded as low as $631.01; lowest intraday level since Jan. 28, 2026, when it hit $628.98
--Down 11.55% at today's intraday low; largest intraday percent decrease since March 12, 2020, when it fell as much as 13.1%
--Second worst performer in the DJIA today
--Seventh worst performer in the S&P 500 today
--Subtracted 296.7 points from the DJIA so far today
All data as of 11:03:23 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 29, 2026 11:06 ET (15:06 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
